Skip to main content
. Author manuscript; available in PMC: 2023 Nov 21.
Published in final edited form as: J Hepatol. 2022 Nov 17;78(3):493–500. doi: 10.1016/j.jhep.2022.10.035

Fig. 1.

Fig. 1.

Cumulative risk of developing HCC stratified on the FIB-4 transition groups from the time of the second FIB-4 test at 3 years. FIB-4 value: low risk <1.45; indeterminate risk 1.45–2.67; high risk: >2.67. FIB-4, fibrosis-4; HCC, hepatocellular carcinoma. (This figure appears in color on the web.)